Canadian Respiratory Journal / 2017 / Article / Tab 2

Research Article

Galactomannan in Bronchoalveolar Lavage Fluid for Diagnosis of Invasive Pulmonary Aspergillosis with Nonneutropenic Patients

Table 2

Comparison of seasonal distribution, clinical symptoms, and chest CT between proven/probable IPA patients and non-IPA patients.

CharacteristicsProven/probable IPA
()
Non-IPA
()

Age ≥ 60 years6 (60.0)63 (44.1 )0.515
Male gender8 (80.0)77 (53.8)0.201
Seasonal distribution, (%)
 March–October7 (70.0)93 (65.0)1.000
Clinical symptoms, (%)
 Cough9 (90.0)101 (70.6)0.340
 Fever2 (20.0)37 (25.9)0.971
 Dyspnoea3 (30.0)16 (11.2)0.212
 Haemoptysis2 (20.0)21 (14.7)1.000
 Chest tightness1 (10.0)12 (8.4)0.600
 Chest pain1 (10.0)18 (12.6)1.000
Chest CT, (%)
 Infiltrate/Nodules8 (80.0)100 (69.9)0.751
 Bronchiectasis3 (30.0)28 (19.6)0.700
 Cavity3 (30.0)18 (12.6)0.284
 Air crescent sign1 (10.0)00.065
 Halo sign1 (10.0)10 (7.0)0.537
 Other1 (10.0)12 (8.4)0.600

IPA, invasive pulmonary aspergillosis; CT, computer tomography. Non-IPA patients are defined as individuals in the “non-IPA” group excluding aspergilloma, ABPA, colonization, or contamination patients.

We are committed to sharing findings related to COVID-19 as quickly as possible. We will be providing unlimited waivers of publication charges for accepted research articles as well as case reports and case series related to COVID-19. Review articles are excluded from this waiver policy. Sign up here as a reviewer to help fast-track new submissions.